Aosaikang

Oryxecon Announces Phase III Clinical Trial Results for Its Innovative Drug Liriotinib

Aosaikang's subsidiary receives registration certificate for methotrexate injection

Aosaikang Shareholder Su Yang Investment Completes 1.50% Share Reduction

Oscient Pharm Inc Q1 Net Profit Up 73.50%

OryxGenetic's Lieretini Tablet Receives Approval for Frontline Treatment Indication

Aosaikang's Subsidiary Obtains Marketing Approval for Isavuconazole Capsules

Aosaikang's Subsidiary Obtains Marketing Authorization for Maribavir Tablets

Aosai Kang's subsidiary obtains registration certificate for Nilotinib Maleate Tablets

Ausican releases clinical trial data of new cMET inhibitor ASKC202 for the treatment of solid tumors

300361

002755

According to the Zhitong Finance APP, ASK PHARM released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 1.434 billion yuan, a year-on-year increase of 3.57%. The net profit attributable to shareholders of the listed company was 223 million yuan, a year-on-year increase of 75.81%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 186 million yuan, a year-on-year increase of 81.89%

Zhitong

ASK PHARM

ASK PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 223 million yuan, a year-on-year increase of 75.81%

ASK PHARM announced that its subsidiary ASKGENE LIMITED will present clinical research data for the biopharmaceutical ASKB589 at the 2025 ESMO Annual Meeting. The drug, in combination with CAPOX and PD-1 inhibitors, has shown deep and lasting tumor remission and disease control in first-line treatment of advanced gastric cancer, with clear survival benefits. These positive clinical data will enhance the market competitiveness of the company's products

Aosaikang: Innovative drug ASKB589 will announce clinical research data at the 2025 ESMO Annual Meeting

Aosaikang's holding subsidiary AskGene Pharma has signed a licensing agreement with Visara, allowing Visara to use the independently developed innovative drug ASKG712 in specific regions. This drug targets VEGF and ANG-2 and is currently undergoing Phase IIa clinical trials in China, showing good safety and efficacy. This collaboration will promote the research and commercialization of ASKG712, aligning with the company's strategic direction and is expected to have a positive impact on future performance

Aosaikang's subsidiary signs ASKG712 project licensing agreement

300436

The innovative drug sector adjusted at the beginning of the trading session, with Aosaikang hitting the limit down, followed by declines in Cosunter, Jimin Health, Huili Pharmaceutical-W, Saili Medical, Rongchang Bio, Wanbangde, and others

Cosunter

Aosaikang announced that in the first half of 2025, operating revenue reached 1.007 billion yuan, a year-on-year increase of 9.20%. Net profit was 160 million yuan, a year-on-year increase of 111.64%

Aosaikang: Net profit of 160 million yuan in the first half of 2025, a year-on-year increase of 111.64%

Aosaikang announced that the cumulative closing price deviation of its stock exceeded 20% over two consecutive trading days on July 15 and 16, 2025, which constitutes abnormal volatility. After verification, the company found no information that needs correction, recent operating conditions are normal, there have been no significant changes in the internal and external environment, and there are no undisclosed significant matters

Aosaikang: Abnormal fluctuations in stock trading

Aosaikang announced that it expects a net profit of 135 million to 175 million yuan in the first half of 2025, an increase of 78.58% to 131.50% compared to 75.5945 million yuan in the same period last year

Aosaikang: Expected net profit in the first half of the year to increase by 78.58%-131.50% year-on-year

Aosaikang announced that the Phase III clinical research results of its innovative drug Liratinib tablets were recently published in the international top medical journal The Lancet Respiratory Medicine. Liratinib tablets are third-generation epidermal growth factor receptor tyrosine kinase inhibitors used for first-line and second-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR mutations

Aosaikang: The results of the Phase III clinical study of Liraglutide Tablets were published in The Lancet Respiratory Medicine

Aosaikang's wholly-owned subsidiary, Jiangsu Aosaikang Pharmaceutical Co., Ltd., recently obtained the Drug Registration Certificate for Methotrexate Injection approved by the National Medical Products Administration. This drug is a dihydrofolate reductase inhibitor with broad-spectrum antitumor activity, which can be used to treat breast cancer, gestational trophoblastic neoplasia, and other conditions, or in combination with other chemotherapy drugs to treat various cancers

Aosaikang's subsidiary Methotrexate Injection has obtained a drug registration certificate

According to the announcement from Aosaikang, as of May 6, 2025, the shareholding reduction plan of the shareholder Su Yang Investment, who holds more than 5% of the shares, has expired. Through centralized bidding and block trading, a total of 13.9223 million shares of the company have been reduced, accounting for 1.50% of the company's total share capital

Aosaikang(300361.SZ)